» Articles » PMID: 32218295

Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment

Abstract

There are limited reports regarding early predictors of objective response (OR) in patients with hepatocellular carcinoma (HCC) treated with lenvatinib. This retrospective study including 70 patients aimed to investigate the efficacy of hepatic biochemical markers. Changes in tumor marker (alpha-fetoprotein (AFP)/des-gamma-carboxy prothrombin (DCP)) levels and albumin-bilirubin (ALBI) score between the baseline value and that estimated one month after treatment were evaluated. We identified several predictors of OR, including changes in tumor marker levels. The OR rate calculated using modified Response Evaluation Criteria in Solid Tumor (mRECIST) was 41.4%. Response was defined as a reduction in AFP and DCP levels of ≥40% from baseline. OR was significantly associated with AFP response, but not with DCP. Predictors of OR were evaluated in two groups (high-AFP group: baseline AFP ≥ 10 ng/mL; low-AFP group: remaining patients). A multivariate analysis identified AFP response (odds ratio, 51.389; = 0.001) and ALBI score (odds ratio, 6.866; = 0.039) as independent predictors of OR in the high-AFP and low-AFP groups, respectively. Changes in the ALBI score indicated deterioration in both responders and non-responders, with a significant difference in non-responders ( = 0.003). AFP response, baseline ALBI score, and change in the ALBI score were early predictors of OR in patients with HCC undergoing lenvatinib treatment.

Citing Articles

Prognostic significance of early alpha fetoprotein and des-gamma carboxy prothrombin responses in unresectable hepatocellular carcinoma patients undergoing triple combination therapy.

Zhang T, Li W, Chen Q, He W, Sun J, Li D Front Immunol. 2024; 15:1508028.

PMID: 39726604 PMC: 11669689. DOI: 10.3389/fimmu.2024.1508028.


Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review).

Ye G, Ye M, Jin X Am J Cancer Res. 2024; 14(9):4113-4171.

PMID: 39417171 PMC: 11477829. DOI: 10.62347/UJVP4361.


Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.

Saeki I, Shimose S, Tomonari T, Ito T, Tani J, Takeuchi Y PLoS One. 2024; 19(9):e0311084.

PMID: 39321197 PMC: 11423983. DOI: 10.1371/journal.pone.0311084.


Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma.

Kuzuya T, Kawabe N, Muto H, Wada Y, Komura G, Nakano T Curr Oncol. 2024; 31(8):4225-4240.

PMID: 39195298 PMC: 11353012. DOI: 10.3390/curroncol31080315.


Amount of ascites impacts survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization advocating for volumetric assessment.

Muller L, Bender D, Gairing S, Foerster F, Weinmann A, Mittler J Sci Rep. 2024; 14(1):16550.

PMID: 39019953 PMC: 11255265. DOI: 10.1038/s41598-024-67312-2.


References
1.
Kudo M . A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer. 2019; 8(5):299-311. PMC: 6872999. DOI: 10.1159/000502905. View

2.
Park H, Park J . Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma. Biomed Res Int. 2014; 2013:310427. PMC: 3885148. DOI: 10.1155/2013/310427. View

3.
Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

4.
Alsina A, Kudo M, Vogel A, Cheng A, Tak W, Ryoo B . Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. Liver Cancer. 2020; 9(1):93-104. PMC: 7024884. DOI: 10.1159/000504624. View

5.
Kudo M . Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma. Liver Cancer. 2019; 8(2):73-77. PMC: 6465712. DOI: 10.1159/000497460. View